Ublituximab

Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects[1].

Product Specifications

CAS Number

[1174014-05-1]

Product Name Alternative

LFB-R603; TG-1101; TGTX-1101

UNSPSC

12352203

Target

CD20

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ublituximab.html

Purity

98.42

Solubility

10 mM in DMSO

Smiles

[Ublituximab]

Molecular Weight

(144.18 kDa)

References & Citations

[1]Matthew Lunning, et al. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 Nov 21;134 (21) :1811-1820.